fashion -WSS

fashion

author：fashion 2025-09-05 09:16:33 - browse：3

KalVista Pharmaceuticals said Tuesday that its oral, on-demand treatment for the swelling “attacks” commonly experienced by patients with a genetic condition called hereditary angioedema achieved the goals of a Phase 3 clinical trial.

Based on the study results, the company plans to submit a marketing application to the Food and Drug Administration by the middle of the year. Regulatory filings in Europe and Japan will be completed later in the year.

In the Phase 3 study involving 136 participants, a low and high dose of Kalvista’s drug, called sebetralstat, showed a median time to the beginning of symptom relief of 1.6 hours and 1.8 hours, respectively, compared to 6.7 hours for a placebo. The result was statistically significant and achieved the study’s main efficacy goal.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： HPV vaccine, cervical cancer study delivers historic results

leisure time

WSS

Maui wildfire now ranks as the fifth

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

Surge in Apellis stock fueled by confidence in safety of its eye drug

Dozens dead from Maui wildfires: What we know about the victims

What to know about the judge who will handle the Trump case

Be careful with at

entertainment

fashion

focus

Heart attack and stroke risk calculators need revising

Health AI: on the border between health care and tech

As demand for Covid shots wanes, Moderna seeks its next success

Biden administration begins canceling student loan debt for 804,000 borrowers

Malaria cases in Florida and Texas: Here’s what you need to know

Novo Nordisk touts Wegovy study, but still struggling with supply

Medicare proposal to cover medical devices draws a mixed reaction

Mass General, Mayo Clinic look to monetize custom

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Pumping milk in bathrooms at health conferences is common

hotspot

TikTok, Instagram influencers need more rules for drug ads

Aspartame and sugar

Novo Nordisk touts Wegovy study, but still struggling with supply

Aspartame and sugar

A pediatrician calls for Congress to pass the child tax credit deal

The inclusion problem at the heart of rehabilitation research

leisure time

focus

focus

explore